Our study shows the feasibility of real-time estimation of antibody kinetics before SARS-CoV-2 variant emergence. This estimation is valuable for understanding how specific combinations of SARS-CoV-2 exposures influence antibody kinetics and for examin...
The complex and ever-evolving immunity landscape associated with SARS-CoV-2, combined with immune evasion by omicron subvariants such as XBB, XBB 1.5, and BQ 1.1,1 is a substantial challenge in defining vaccine compositions and developing effective vac...
The escalating incidence of mpox in Africa has led the Africa Centres for Disease Control and Prevention to declare its first-ever Public Health Emergency of Continental Security and prompted WHO to issue its highest global health alert—a Public Health...
Mosquito-borne viruses pose a substantial global threat, to which arboviruses are major contributors. Pathogens such as dengue virus, yellow fever virus, and Zika virus contributed to upwards of 59 million estimated infections in 2021,1 with other deng...
Mpox is a viral infection that causes acute disease in humans and can be fatal. On Aug 14, 2024, the WHO declared the ongoing mpox outbreak to be a global public health emergency. Shifting transmission patterns via sexual routes are a novel feature of ...
The findings of this study highlight the widespread burden posed by URIs and otitis media across all age groups and both sexes. There is a continued need for surveillance, prevention, and management to better understand and reduce the burden associated...
Post-COVID-19 condition (also known as long COVID)—the term that encapsulates the long-term health effects caused by SARS-CoV-2 infection—is a complex multisystemic chronic disease with profound consequences.1,2 Shortly after long COVID was first repor...
In a vaccinated population, people treated with molnupiravir for acute COVID-19 felt better, experienced fewer and less severe COVID-19 associated symptoms, accessed health care less often, and took less time off work at 6 months. However, the absolute...
Upper respiratory infections (URIs) are some of the most common infections and are caused by a variety of pathogens. Treatment for URIs is usually symptomatic only, if needed, unless a person also has a chronic respiratory condition, such as asthma, wh...
We read with interest the Correspondence by Concetta Castilletti and colleagues1 and the Editorial2 on the current Oropouche virus outbreak and imported cases in Europe. As of July 25, 2024, human-to-human transmission has not been identified, and alth...
On Aug 14, WHO declared the worsening mpox situation in Africa a Public Health Emergency of International Concern. Esther Nakkazi reports.
H3N2 influenza viruses represent serious respiratory pathogens for the elderly because active circulation of H3N2 viruses is associated with an increased risk of hospitalisation and influenza-related mortality in this age group.1 Several antigenic clad...
These data support the continued clinical development of mRNA-based next-generation seasonal influenza vaccines with broadened influenza A/H3N2 strain coverage.
The available evidence for non-ICU CAP and AECOPD supports a short-course treatment duration of 5 days in patients who have clinically improved. Efforts of the scientific community should be directed at implementing this evidence in daily practice. Hig...
VLA1553 was generally safe and induced seroprotective titres in almost all vaccinated adolescents with favourable safety data in adolescents who were seropositive at baseline. The data support the use of VLA1553 for the prevention of disease caused by ...
The battle against antimicrobial resistance (AMR) demands critical evaluation of antibiotic treatment protocols, particularly for respiratory tract infections (RTIs). The umbrella review in The Lancet Infectious Diseases by Suzanne M E Kuijpers and col...